| 生物活性 |
Vitisin A ((+)-Vitisin A) is an orally active natural product possessing multiple pharmacological activities including anti-inflammatory, anti-tumor, antioxidant, anti-pathogenic microorganism, glucose-lowering and lipid-regulating, anti-osteoporotic, neuroprotective, and cardiovascular protective effects; it exhibits an IC50 of 1.29 µM against human AChE and 4.94 µM against human MAO-B, inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR, and TRAF6 pathways while downregulating related phosphorylation and protein expression, and simultaneously activates the Nrf2/HO-1 pathway and upregulates p21 expression; it induces tumor cell apoptosis and cell cycle arrest, suppresses adipogenesis and lipid accumulation, while attenuating oxidative stress, inhibiting inflammatory responses, and blocking liver fibrosis, cuproptosis, and cholesterol synthesis, and elevates central BDNF and TrkB expression levels; therefore, Vitisin A can be used in research on tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, and neurodegenerative and cognitive dysfunction-related diseases. |
体外研究 (In Vitro) |
Vitisin A 可通过清除自由基和还原铁离子发挥抗氧化活性,其 FRAP 和 DPPH 值分别为 2.38 mM Trolox/g phenol 和 1.24 mM Trolox/g phenol。 Vitisin A 对人类癌细胞系具有高细胞毒性,对 MES-SA 细胞的 IC50 为 1.11 μM,并可通过亚 G1 期细胞周期阻滞诱导细胞凋亡。 Vitisin A 可通过 ROS 水平升高、caspase 3 活性增强及 Bax/Bcl-2 比值改变,诱导人肝癌 HepG2 细胞发生 G2/M 期细胞周期阻滞和凋亡,但对 Hep3B 细胞无作用。 Vitisin A (4, 8 μM; 24 h) 可通过上调 DR5 表达并诱导 ROS 生成,增强 TRAIL 介导的细胞凋亡,从而在 PC-3、DU145 和 LNCaP 人前列腺癌细胞中发挥 TRAIL 增敏剂的作用。 Vitisin A 通过调控 Akt 和 STAT1 的磷酸化,抑制甲型流感病毒诱导人肺泡上皮细胞 A549 产生 RANTES。 Vitisin A 通过诱导 G1 期阻滞并调控 p21、PPARγ 和 C/EBPα 的表达来抑制前脂肪细胞的增殖与分化,具有抗肥胖活性。 Vitisin A 通过调控 LDLR、HMG-CoA 还原酶及 PCSK9 发挥降胆固醇作用,并通过调控脂肪生成与脂肪酸氧化通路降低 HepG2 细胞中的甘油三酯水平。 Vitisin A 可通过靶向 TRAF6-TAK1-NFATc1 信号通路抑制 RAW264.7 小鼠巨噬细胞及原代小鼠骨髓细胞中的破骨细胞分化,从而支持抗骨质疏松活性。 Vitisin A 可提高经 H2O2 处理的人神经细胞 SH-SY5Y 的存活率,并在 10 μM 浓度下对原代大鼠皮层细胞中谷氨酸诱导的神经毒性发挥部分保护作用。 Vitisin A 可抑制雄激素受体活性,并保护人毛乳头细胞免受双氢睾酮 (DHT) 诱导的损伤,支持其在雄激素性脱发治疗中的潜在应用。 Vitisin A 对 Plasmopara viticola 具有抗真菌活性。 Vitisin A (0-10 nM; 0-24 h) 可呈剂量依赖性和时间依赖性恢复经 TGF-β1 激活的 LX-2 细胞的活力。 Vitisin A 可减轻 ES-Cu 对 TGF-β1 激活的 LX-2 细胞的细胞毒性。 Vitisin A 可通过上调 Nrf2/HO-1 信号通路,以剂量依赖方式抑制经 TGF-β1 激活的 LX-2 细胞中的纤维化、铜死亡、脂质合成及氧化应激;且上述作用会被通过 siRNA 敲低 Nrf2 的操作消除,证实 Nrf2/HO-1 通路是关键的介导因子。 Vitisin A (1-10 μM; 8 days) 可强效抑制 3T3-L1 前脂肪细胞分化,其 IC50 为 5.0 μM,能以剂量依赖方式减少脂质积累。 Vitisin A (1-10 μM; 8 days) 可呈剂量依赖性降低分化 3T3-L1 细胞中 PPARγ 和 C/EBPα 的蛋白表达水平。 Vitisin A (1-10 μM; 24 h) 可微弱但显著地抑制 Rosiglitazone (MS-H37828) 在瞬时转染的 COS-7 细胞中诱导的 PPARγ 转录活性。 Vitisin A (5-10 μM; 24-48 h) 可显著抑制分化培养基诱导的 3T3-L1 前脂肪细胞增殖,使其增殖水平降至接近生长停滞状态。 Vitisin A (1-50 μM; 24 h) 对 3T3-L1 前脂肪细胞无细胞毒性的最高浓度为 25 μM,仅在 50 μM 浓度下检测到细胞毒性。 Vitisin A (10 μM; 0-2 days, 2-5 days, 5-8 days, or 0-8 days) 主要通过靶向成脂诱导最初 2 天内的前脂肪细胞增殖阶段来抑制 3T3-L1 脂肪细胞分化,在此阶段后给药则作用极弱。 Vitisin A (5-10 μM; 24 hours) 可阻滞 3T3-L1 前脂肪细胞在 G1-S 转换期的细胞周期进程,使细胞维持在 G0/G1 期,与未分化的生长停滞细胞状态相似。 Vitisin A (1-10 μM; 6-24 hours) 可呈剂量依赖性降低分化诱导的 3T3-L1 前脂肪细胞中 cyclin A 和 cyclin B 的表达,延迟 CDK2 的表达,且不影响 cyclin E 的表达,这一结果支持其可诱导 G1 期细胞周期阻滞。 Vitisin A (1-10 μM; 0.25-3 hours, 24 hours) 通过恢复 p21 表达并降低 Rb 磷酸化来调控分化诱导的 3T3-L1 前脂肪细胞的有丝分裂调控。 Vitisin A (1-10 μM; 24 h) 可剂量依赖性地抑制 LPS 诱导的 RAW 264.7 巨噬细胞中 NO 的生成。 Vitisin A (1-10 μM; 8 h) 呈剂量依赖性抑制 RAW 264.7 巨噬细胞中 LPS 诱导的 iNOS 表达。 Vitisin A (1-10 μM; 20 min) 可剂量依赖性地抑制 RAW 264.7 巨噬细胞中 LPS 诱导的 ERK1/2 和 p38 磷酸化。 Vitisin A (10 μM; 15 min) 可通过抑制 IκB-α 的磷酸化与降解,阻断 LPS 诱导的 RAW 264.7 巨噬细胞中 NF-κB 活化。 Vitisin A 可强效抑制重组人乙酰胆碱酯酶,其 IC50 为 1.29 μM。 Vitisin A 可强效抑制重组人 MAO-B,其 IC50 为 4.94 μM。 Vitisin A (2.5-20 μM; 24 h pre-treatment) 可显著保护人 SH-SY5Y 神经母细胞瘤细胞免受 MGO 诱导的细胞死亡。
Cell Cytotoxicity Assay
| Cell Line: |
Human prostate cancer cell lines (PC-3, DU145, LNCaP) |
| Concentration: |
4, 8 μM (combined with 20, 40 ng/mL TRAIL) |
| Incubation Time: |
24 h |
| Result: |
Enhanced cytotoxicity and sub-G1 accumulation in PC-3, DU145, and LNCaP cells with TRAIL, most potently in PC-3 cells. Upregulated caspase 3, FADD, DR4, and DR5 expression when combined with TRAIL. Downregulated pro-caspase 7/8, DcR1, Bcl-XL, and Bcl-2 expression with TRAIL combination. Elevated DR5 promoter activity, cell-surface DR5, and ROS production with TRAIL. Induced PARP cleavage when combined with TRAIL.
|
Cell Viability Assay
| Cell Line: |
TGF-β1-activated human hepatic stellate cell line LX-2 |
| Concentration: |
0, 2.5, 5.0, 7.5, 10 nM |
| Incubation Time: |
0, 2, 4, 6, 8, 12, 24 h |
| Result: |
Restored cell viability in a dose-dependent manner with increasing viability from 0 to 10 nM. Restored cell viability in a time-dependent manner with increasing viability from 0 to 24 h incubation. |
Cell Differentiation Assay
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
8 days |
| Result: |
Inhibited 3T3-L1 adipocyte differentiation in a dose-dependent manner. Reduced relative lipid content to ~70% at 1 μM, ~35% at 5 μM, and nearly 0% at 10 μM relative to untreated control. Almost completely suppressed differentiation at 10 μM. Showed an IC50 of 5.0 μM for adipocyte differentiation inhibition.
|
Western Blot Analysis
| Cell Line: |
differentiated 3T3-L1 cells |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
8 days |
| Result: |
Reduced the expression of PPARγ and C/EBPα, key adipogenic transcription factors. Lowered protein levels of both factors at 1 μM. |
Cell Proliferation Assay
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
5, 10 μM |
| Incubation Time: |
24, 48 hours |
| Result: |
Significantly inhibited differentiation medium-induced mitosis of 3T3-L1 preadipocytes, reducing proliferation nearly to the level of normal growth-arrested cells. Suppressed proliferation at both 5 and 10 μM, with no significant difference between the two concentrations at 24 and 48 hours. |
Cell Cytotoxicity Assay
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
1, 5, 10, 25, 50 μM |
| Incubation Time: |
24 hours |
| Result: |
Showed no cytotoxicity at concentrations up to 25 μM, as released LDH remained at control levels. Increased released LDH to ~140% of the control at 50 μM, indicating cytotoxicity. |
Cell Differentiation Assay
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
10 μM |
| Incubation Time: |
0-2 days, 2-5 days, 5-8 days, or 0-8 days |
| Result: |
Reduced relative lipid content to 2.7% of the control when applied during days 0-2, nearly equivalent to the effect of continuous treatment over 8 days (1.6% of control). Resulted in much weaker inhibition when applied from days 2-5 or 5-8, with relative lipid contents of 70.4% and 72.8% of the control, respectively. |
Cell Cycle Analysis
| Cell Line: |
differentiation-induced 3T3-L1 preadipocytes |
| Concentration: |
5, 10 μM |
| Incubation Time: |
24 hours |
| Result: |
Blocked differentiation medium-induced cell cycle progression at the G1-S transition. Maintained 84.0% of cells in G0/G1 phase at 5 μM, with 7.7% in S phase and 7.9% in G2/M phase. Maintained 89.6% of cells in G0/G1 phase at 10 μM, with 6.6% in S phase and 3.8% in G2/M phase.
|
Western Blot Analysis
| Cell Line: |
differentiation-induced 3T3-L1 preadipocytes |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
6, 12, 18, 24 hours |
| Result: |
Dose-dependently repressed the differentiation medium-induced increase in cyclin A and cyclin B expression. Significantly reduced cyclin A and B levels at 10 μM starting at 12-18 hours post-induction. Delayed CDK2 expression, while cyclin E expression was unaffected. |
Western Blot Analysis
| Cell Line: |
differentiation-induced 3T3-L1 preadipocytes |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
0.25, 0.5, 1, 2, 3 hours; 24 hours |
| Result: |
Did not affect ERK or Akt phosphorylation at any tested time point. Restored the differentiation-induced decrease in p21 expression in a dose-dependent manner. Reduced differentiation-induced phosphorylation of retinoblastoma protein (Rb) at Ser780 in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: |
RAW 264.7 macrophage cells |
| Concentration: |
1, 5, 10 μM (8 h incubation after LPS stimulation); 10 μM (non-LPS-treated cell...(内容过长已截断) |
体内研究 (In Vivo) |
Vitisin A (40 mg/kg;单次给药) 可通过减轻氧化应激、抑制乙酰胆碱酯酶活性并增强突触信号传导,改善东莨菪碱诱导的失忆小鼠的认知功能。 Vitisin A (中枢给药) 可通过激活 BDNF-CREB 信号通路,恢复东莨菪碱处理的 C57BL/6 小鼠的认知功能及海马突触可塑性。 Vitisin A (局部给药) 通过维持毛囊结构并调控 Wnt/β-catenin 信号通路,保护小鼠免受 DHT 诱导的雄激素性脱发影响。 Vitisin A (膳食摄入,100 mg/kg) 可通过调控肝脏脂质代谢通路,降低高脂饮食喂养小鼠的体重增长幅度及血浆甘油三酯水平。 Vitisin A 可降低高脂饮食喂养小鼠的体重并改善其血浆脂质谱。 Vitisin A (腹腔注射) 可通过激活 Nrf2/HO-1 通路、抑制铜死亡、脂质过氧化及肝星状细胞活化,以剂量依赖方式抑制 CCl4 诱导小鼠的肝纤维化。 Vitisin A (40 mg/kg;口服;每日一次;连续 13 天) 可显著改善东莨菪碱诱导的雄性 ICR 小鼠失忆症状,表现为 retention trial 穿梭潜伏期延长、脑内 AChE 活性与氧化应激水平降低,以及 BDNF/TrkB 蛋白表达恢复。 Vitisin A (10 mg/kg;口服;单次给药) 可显著降低自发性高血压大鼠的收缩压和舒张压,给药后 8 小时观察到峰值效应。 Vitisin A (25 mg/kg;口服;每日一次;连续 36 天) 可减少高脂饮食喂养的 C57BL/6 小鼠的体重增长,并改善其肥胖相关的血浆脂质参数。
| Animal Model: |
ICR mice (scopolamine-induced amnesia) |
| Dosage: |
40 mg/kg |
| Administration: |
single administration |
| Result: |
Significantly improved impaired learning behaviors in scopolamine-treated mice. Decreased acetylcholinesterase activity and malondialdehyde levels in brain extracts. Increased expression of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B. Enhanced expression of synaptic plasticity proteins synapsin I, calcium/calmodulin-dependent protein kinase II, and Akt. |
| Animal Model: |
ICR (6-week-old male, scopolamine-induced amnesia) |
| Dosage: |
40 mg/kg |
| Administration: |
p.o.; daily; 13 days |
| Result: |
Increased step-through latency in the retention trial of the passive avoidance test compared with scopolamine-treated control mice. Reduced acetylcholinesterase (AChE) activity and malondialdehyde (MDA) levels in brain tissue extracts compared with the control group. Restored protein expressions of brain-derived neurotrophic factor (BDNF; BDNF/β-actin = 1.25) and its receptor tropomyosin receptor kinase B (TrkB; TrkB/β-actin = 1.16) from scopolamine-induced decreases.
|
| Animal Model: |
C57BL/6 (high-fat diet-induced obesity) |
| Dosage: |
25 mg/kg |
| Administration: |
p.o.; daily; 36 days |
| Result: |
Reduced weight gain in high-fat diet-fed mice. Improved plasma cardiovascular risk parameters, including reduced total cholesterol, total triglycerides, low-density lipoproteins, and free fatty acids. |
|
| 性状 |
固体 |
| 颜色 |
Brown to black |
| 分子量 |
906.93 |
| 分子式 |
C56H42O12 |
| CAS No. |
142449-89-6 |
| 别名 |
(+)-Vitisin A |
| 储存方式 |
-20°C, protect from light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|